Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims
Executive Summary
Sandoz's request that US FDA remove psoriatic arthritis and plaque psoriasis indications from biosimilar's approved labeling appears aimed at defending against patent infringement claims brought by Amgen, legal experts say.
You may also be interested in...
Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid
Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.
Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
The latest drug development news and highlights from our US FDA Performance Tracker.
No More Deal? Novartis, Amgen Trade Lawsuits Over Aimovig Agreements
Novartis wants a federal judge to stop Amgen from terminating the companies' agreements around potential migraine blockbuster Aimovig, in which it claims to have invested $870m to date. Amgen wants to go to trial, letting a jury decide whether it can end the partnership – and win damages.